{rfName}

Indexed in

License and use

Altmetrics

Grant support

The Paris PVT meeting was supported by FILFOIE, ERN-RARE Liver, Societe Nationale Francaise de Gastroenterologie, and Association Francaise pour l'etude du Foie. This Review was written on behalf of the ERN RARE-LIVER group, and was a study supported by VALDIG, an EASL consortium. .

Analysis of institutional authors

Hernandez-Gea, VirginiaAuthorBaiges, AnnaAuthorGarcia-Pagan, Juan-CarlosAuthor

Share

October 22, 2024
Publications
>
Review
No

Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies

Publicated to:Lancet Gastroenterology & Hepatology. 9 (9): 859-883 - 2024-09-01 9(9), DOI: 10.1016/S2468-1253(24)00155-9

Authors: Elkrief, Laure; Hernandez-Gea, Virginia; Senzolo, Marco; Albillos, Agustin; Baiges, Anna; Berzigotti, Annalisa; Bureau, Christophe; Murad, Sarwa Darwish; De Gottardi, Andrea; Durand, Francois; Garcia-Pagan, Juan-Carlos; Lisman, Ton; Mandorfer, Mattias; Mclin, Valerie; Moga, Lucile; Nery, Filipe; Northup, Patrick; Nuzzo, Alexandre; Paradis, Valerie; Patch, David; Payance, Audrey; Plaforet, Vincent; Plessier, Aurelie; Poisson, Johanne; Roberts, Lara; Salem, Riad; Sarin, Shiv; Shukla, Akash; Toso, Christian; Tripathi, Dhiraj; Valla, Dominique; Ronot, Maxime; Rautou, Pierre-Emmanuel

Affiliations

Bern Univ Hosp, Inselspital, Dept Visceral Surg & Med, Bern, Switzerland - Author
Ctr Hosp Reg Univ Tours, Fac Med Tours, Serv Hepatogastroenterol, Tours, France - Author
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain - Author
Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands - Author
Hop Beaujon, Dept Pathol, AP HP, Clichy, France - Author
Hop Beaujon, Intestinal Stroke Ctr, Dept Gastroenterol IBD & Intestinal Failure, AP HP, Clichy, France - Author
Hop Beaujon, Serv Hepatol, AP HP, F-92110 Clichy, France - Author
Hop Beaujon, Serv Radiol, AP HP, Clichy, France - Author
Hop Corentin Celton AP HP, Serv Geriatrie, Paris, France - Author
Hop Univ Geneve, Serv Chirurg Viscerale, Geneva, Switzerland - Author
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Liver Unit, Barcelona Hepat Hemodynam Lab, Barcelona, Spain - Author
Hosp Univ Ramon & Cajal, Dept Gastroenterol & Hepatol, Inst Ramon & Cajal Invest Sanit, Madrid, Spain - Author
Inst Liver & Biliary Sci, New Delhi, India - Author
Kings Coll Hosp NHS Fdn Trust, Dept Haematol Med, London, England - Author
Lab Vasc & Translat Sci, INSERM UMR 1148, Paris, France - Author
Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria - Author
Northwestern Univ, Northwestern Mem Hosp, Chicago, IL USA - Author
NYU Langone, Div Gastroenterol, New York, NY USA - Author
NYU Langone, Transplant Inst, New York, NY USA - Author
Royal Free Hosp, Dept Hepatol & Liver Transplantat, London, England - Author
Seth GS Med Coll & KEM Hosp, Dept Gastroenterol, Mumbai, India - Author
Univ Barcelona, Dept Med & Ciencies Salut, Barcelona, Spain - Author
Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, England - Author
Univ Geneva, Swiss Pediat Liver Ctr, Dept Pediat, Gynecol & Obstet, Geneva, Switzerland - Author
Univ Hosp Birmingham, Queen Elizabeth Hosp, Dept Liver & Hepatopancreato Biliary Unit, Birmingham, England - Author
Univ Med Ctr Groningen, Dept Surg, Groningen, Netherlands - Author
Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy - Author
Univ Paris Cite, Ctr Rech Inflammat, Paris, France - Author
Univ Paul Sabatier, Serv Hepatol, Hop Rangueil, Toulouse, France - Author
Univ Porto, Sch Med & Biomed Sci, Immuno Physiol & Pharmacol Dept, Porto, Portugal - Author
Univ Svizzera Italiana, Gastroenterol & Hepatol Dept, Ente Osped Cantonale, Fac Biomed Sci, Lugano, Switzerland - Author
See more

Abstract

Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the portal vein, its branches, its radicles, or a combination. This Review first provides a comprehensive overview of all aspects of PVT, namely the specifics of the portal venous system, the risk factors for PVT, the pathophysiology of portal hypertension in PVT, the interest in non-invasive tests, as well as therapeutic approaches including the effect of treating risk factors for PVT or cause of cirrhosis, anticoagulation, portal vein recanalisation by interventional radiology, and prevention and management of variceal bleeding in patients with PVT. Specific issues are also addressed including portal cholangiopathy, mesenteric ischaemia and intestinal necrosis, quality of life, fertility, contraception and pregnancy, and PVT in children. This Review will then present endpoints for future clinical studies in PVT, both in patients with and without cirrhosis, agreed by a large panel of experts through a Delphi consensus process. These endpoints include classification of portal vein thrombus extension, classification of PVT evolution, timing of assessment of PVT, and global endpoints for studies on PVT including clinical outcomes. These endpoints will help homogenise studies on PVT and thus facilitate reporting, comparison between studies, and validation of future studies and trials on PVT.

Keywords

Acute mesenteric ischemiaAnticoagulantsCirrhotic-patientsDirect oral anticoagulantsFemaleGastrointestinal hemorrhageHumansHypertension, portalIntrahepatic portosystemic shuntLiver cirrhosisLiver-transplantationMolecular-weight heparinPolycythemia-verPortal veinPregnancyQuality of lifeRisk factorsRisk-factorsTranscatheter thrombolytic therapyVenous system thrombosisVenous thrombosis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Lancet Gastroenterology & Hepatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 2/143, thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology & Hepatology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-19:

  • WoS: 6
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-19:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 48.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 59 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 108.5.
  • The number of mentions on the social network X (formerly Twitter): 174 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Austria; France; India; Italy; Netherlands; Portugal; Switzerland; United Kingdom; United States of America.